Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.34
-1.4%		$0.38
$0.30
▼
$1.04
$21.09M1.3999,334 shs113,579 shs
electroCore, Inc. stock logo
ECOR
electroCore
$9.63
-0.8%		$7.84
$4.41
▼
$10.95
$86.78M0.92103,361 shs87,117 shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$6.00
-0.3%		$6.71
$2.21
▼
$9.33
$75.35M1.49132,540 shs40,207 shs
Outset Medical, Inc. stock logo
OM
Outset Medical
$3.94
-3.7%		$4.52
$3.00
▼
$16.16
$74.06M1.96141,942 shs146,265 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-9.30%-4.14%-31.64%-63.91%
electroCore, Inc. stock logo
ECOR
electroCore
0.00%-8.46%+53.10%-1.33%+73.51%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%-2.44%-4.46%-19.03%+147.93%
Outset Medical, Inc. stock logo
OM
Outset Medical
0.00%-6.41%-17.05%-19.43%-71.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.34
-1.4%		$0.38
$0.30
▼
$1.04
$21.09M1.3999,334 shs113,579 shs
electroCore, Inc. stock logo
ECOR
electroCore
$9.63
-0.8%		$7.84
$4.41
▼
$10.95
$86.78M0.92103,361 shs87,117 shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$6.00
-0.3%		$6.71
$2.21
▼
$9.33
$75.35M1.49132,540 shs40,207 shs
Outset Medical, Inc. stock logo
OM
Outset Medical
$3.94
-3.7%		$4.52
$3.00
▼
$16.16
$74.06M1.96141,942 shs146,265 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-9.30%-4.14%-31.64%-63.91%
electroCore, Inc. stock logo
ECOR
electroCore
0.00%-8.46%+53.10%-1.33%+73.51%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%-2.44%-4.46%-19.03%+147.93%
Outset Medical, Inc. stock logo
OM
Outset Medical
0.00%-6.41%-17.05%-19.43%-71.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.00
Hold$5.381,501.61% Upside
electroCore, Inc. stock logo
ECOR
electroCore
2.00
Hold$18.0086.92% Upside
NeurAxis, Inc. stock logo
NRXS
NeurAxis
3.00
Buy$13.00116.67% Upside
Outset Medical, Inc. stock logo
OM
Outset Medical
2.40
Hold$10.00153.81% Upside

Current Analyst Ratings Breakdown

Latest CTSO, ECOR, OM, and NRXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Outset Medical, Inc. stock logo
OM
Outset Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/7/2026
Outset Medical, Inc. stock logo
OM
Outset Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/6/2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
electroCore, Inc. stock logo
ECOR
electroCore
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
Outset Medical, Inc. stock logo
OM
Outset Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$37.06M0.57N/AN/A($0.01) per share-33.56
electroCore, Inc. stock logo
ECOR
electroCore
$36.97M2.35N/AN/A($0.31) per share-31.06
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$5.32M14.17N/AN/A($0.27) per share-22.22
Outset Medical, Inc. stock logo
OM
Outset Medical
$117.80M0.63N/AN/A$5.13 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$8.20M-$0.29N/AN/AN/A-48.94%-431.65%-41.94%11/12/2026 (Estimated)
electroCore, Inc. stock logo
ECOR
electroCore
-$13.97M-$1.66N/AN/AN/A-39.96%-1,956.38%-81.35%11/4/2026 (Estimated)
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$14.63M-$0.78N/AN/AN/A-492.76%N/A-641.25%11/17/2026 (Estimated)
Outset Medical, Inc. stock logo
OM
Outset Medical
-$81.65M-$4.09N/AN/AN/A-63.06%-61.67%-28.25%11/9/2026 (Estimated)

Latest CTSO, ECOR, OM, and NRXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.04-$0.07-$0.03-$0.07$9.39 million$9.63 million
8/6/2026Q2 2026
electroCore, Inc. stock logo
ECOR
electroCore
-$0.4218-$0.33+$0.0918-$0.33$9.49 million$9.45 million
8/6/2026Q2 2026
Outset Medical, Inc. stock logo
OM
Outset Medical
-$0.7167-$0.80-$0.0833-$0.97$28.97 million$31.64 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
electroCore, Inc. stock logo
ECOR
electroCore
N/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/AN/AN/AN/AN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
4.70
0.66
0.50
electroCore, Inc. stock logo
ECOR
electroCore
N/A
1.21
1.00
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/A
0.24
0.23
Outset Medical, Inc. stock logo
OM
Outset Medical
1.03
5.19
4.11

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
electroCore, Inc. stock logo
ECOR
electroCore
26.74%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
11.77%
Outset Medical, Inc. stock logo
OM
Outset Medical
N/A

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.80%
electroCore, Inc. stock logo
ECOR
electroCore
7.80%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
21.10%
Outset Medical, Inc. stock logo
OM
Outset Medical
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.84 million57.94 millionOptionable
electroCore, Inc. stock logo
ECOR
electroCore
509.02 million8.31 millionNot Optionable
NeurAxis, Inc. stock logo
NRXS
NeurAxis
1912.56 million6.09 millionNot Optionable
Outset Medical, Inc. stock logo
OM
Outset Medical
52018.80 million18.33 millionNot Optionable

Recent News About These Companies

Outset Medical Announces Departure of General Counsel Brottem
August 28 at 5:10 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/outset-medical-announces-departure-of-general-counsel-brottem?utm_source=marketbeat.com&utm_medium=referral
Outset Medical (NASDAQ:OM) General Counsel John Brottem Sells 2,632 Shares
August 19, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-om-insider-buying-and-selling-2026-08-19/
Leslie Trigg Sells 3,437 Shares of Outset Medical (NASDAQ:OM) Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/leslie-trigg-sells-3437-shares-of-outset-medical-nasdaqom-stock-2026-08-18/
Outset Medical Earnings Call Highlights Refresh Tailwinds
August 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/outset-medical-earnings-call-highlights-refresh-tailwinds?utm_source=marketbeat.com&utm_medium=referral
Insider Selling: Outset Medical (NASDAQ:OM) General Counsel Sells $11,554.48 in Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-outset-medical-nasdaqom-general-counsel-sells-1155448-in-stock-2026-08-18/
Outset Medical (NASDAQ:OM) CFO Renee Gaeta Sells 4,543 Shares of Stock
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/outset-medical-nasdaqom-cfo-renee-gaeta-sells-4543-shares-of-stock-2026-08-18/
Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock
August 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2976132/despite-fast-paced-momentum-outset-medical-om-is-still-a-bargain-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|fast_paced_momentum_at_a_bargain-2976132
Outset Medical (NASDAQ:OM) Raised to Hold at Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/outset-medical-nasdaqom-raised-to-hold-at-wall-street-zen-2026-08-15/
Outset Medical (OM) Q2 2026 Earnings Call Transcript
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/outset-medical-om-q2-2026-232956599.html
Outset Medical, Inc. (NASDAQ:OM) Given Average Recommendation of "Hold" by Analysts
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/outset-medical-inc-nasdaqom-given-average-recommendation-of-hold-by-analysts-2026-08-13/
Stifel Nicolaus Keeps Their Buy Rating on Outset Medical (OM)
August 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OM-Q/pressreleases/3738959/stifel-nicolaus-keeps-their-buy-rating-on-outset-medical-om/
Outset Medical (NASDAQ:OM) Issues Quarterly Earnings Results
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/outset-medical-nasdaqom-issues-quarterly-earnings-results-2026-08-07/
Outset Medical, Inc. (OM) Q2 2026 Earnings Call Transcript
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932935-outset-medical-inc-om-q2-2026-earnings-call-transcript
Outset Medical Q2 Earnings Call Highlights
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/outset-medical-q2-earnings-call-highlights-2026-08-07/
Outset Medical rapporteert gemengde Q2 2026-resultaten, aandeel licht hoger
August 6, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/outset-medical-rapporteert-gemengde-q2-2026resultaten-aandeel-licht-hoger-93CH-881367
Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970413/outset-medical-inc-om-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2970413
Outset Medical (OM) Stock Falls on Q2 2026 Earnings
August 6, 2026  |  quiverquant.comQ
Outset Medical Reports Second Quarter 2026 Results
August 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/outset-medical-reports-second-quarter-2026-results-1036422610
Der aktuelle Kurs der Outset Medical Inc Aktie beträgt 5,060.
August 5, 2026  |  de.investing.comhttps://de.investing.com/equities/outset-medical-inc
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
July 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-outset-medical-inc-insiders-breach-their-fiduciary-duties-to-shareholders-302837822.html
Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
July 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/outset-medical-to-report-second-quarter-2026-financial-results-on-thursday-august-6-2026-1036356995

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$0.34 0.00 (-1.41%)
As of 08/28/2026 04:00 PM Eastern

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

electroCore stock logo

electroCore NASDAQ:ECOR

$9.63 -0.08 (-0.82%)
As of 08/28/2026 04:00 PM Eastern

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

NeurAxis stock logo

NeurAxis NASDAQ:NRXS

$6.00 -0.02 (-0.33%)
As of 08/28/2026 04:00 PM Eastern

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Outset Medical stock logo

Outset Medical NASDAQ:OM

$3.94 -0.15 (-3.67%)
As of 08/28/2026 04:00 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas